Results 1 to 10 of about 1,770 (157)

Modelling the 5‐Year Impact of Twice‐Yearly Injectable Lenacapavir for HIV Pre‐Exposure Prophylaxis in the United States [PDF]

Journal of the International AIDS Society
Introduction The impact of pre‐exposure prophylaxis (PrEP) on the US HIV‐1 epidemic has not been fully maximized, potentially due to challenges in uptake, coverage, adherence and consistent use. Following the FDA (Food and Drug Adminstration) approval of
Mia Moore, Serin Lee, Laura Matrajt, Sarah E. Stansfield, Li Tao, Juan Yang, Dylan Mezzio, James Jarrett, JeanPierre Coaquira Castro, Alice Hsiao, Woodie Zachry, Dobromir Dimitrov   +11 more
doaj   +3 more sources

Lenacapavir-induced lattice hyperstabilization is central to HIV-1 capsid failure at the nuclear pore complex and in the cytoplasm [PDF]

eLife
Lenacapavir (LEN) is the first human immunodeficiency virus type 1 (HIV-1) capsid inhibitor approved for clinical use in humans. It inhibits multiple steps of the viral life cycle; however, the molecular details of the effect of LEN on capsid structure ...
Arpa Hudait, Ryan C Burdick, Ellie K Bare, Vinay K Pathak, Gregory A Voth   +4 more
doaj   +3 more sources

Impact of HIV-1 capsid polymorphisms on viral infectivity and susceptibility to lenacapavir

MBio
Lenacapavir (LEN) is a first-in-class capsid (CA) inhibitor for the treatment and prevention of HIV-1 infection. While LEN has shown potent antiviral activity across all major HIV-1 subtypes, the impact of existing HIV-1 CA sequence diversity on the ...
Jason K Perry, Stephen R Yant, Matthew Hendricks   +2 more
exaly   +4 more sources

Lenacapavir for HIV Prevention: A Commitment to Equitable Access and Partnership by Gilead Sciences [PDF]

Clinical Infectious Diseases
Lenacapavir, a first-in-class HIV capsid inhibitor, is under development by Gilead Sciences for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). This article responds to inquiries into Gilead's access efforts for low- and
Jared Baeten
exaly   +3 more sources

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +2 more sources

HIV Capsid Protein Genetic Diversity Across HIV-1 Variants and Impact on New Capsid-Inhibitor Lenacapavir

Frontiers in Microbiology, 2022
The HIV p24 capsid protein has an essential, structural, and functional role in the viral replication cycle, being an interesting target for vaccine design, diagnostic tests, and new antiretroviral drugs (ARVs).
Paloma Troyano-Hernáez, Africa Holguin, Roberto Reinosa   +2 more
exaly   +3 more sources

Lenacapavir: a potential game changer for HIV prevention in the Americas, if the game is played equitably

The Lancet Regional Health. Americas
Summary: Lenacapavir, a first in class long-acting capsid inhibitor has near 100% efficacy in preventing HIV. As such, it has the potential to curb the rising HIV incidence in Latin America, a region with stark intra- and inter-country PrEP uptake ...
Valeria D. Cantos, Brenda Crabtree Ramírez, Colleen F. Kelley, Carlos del Rio, Beatriz Grinsztejn   +4 more
doaj   +2 more sources

Awareness, knowledge, perception and behavioral risk predictors of acceptability of long-acting injectable lenacapavir HIV pre-exposure prophylaxis in Ghana: a cross-sectional study [PDF]

AIDS Research and Therapy
Long-acting injectable HIV pre-exposure prophylaxis (PrEP), particularly lenacapavir, has demonstrated near-complete efficacy, yet its public health impact depends on community awareness, knowledge and acceptance.
Ebenezer Senu, Cornelia Quainoo Donkor, Success Acheampomaa Oppong, Daniel Dzemedo Nouwati, Emmanuel Ntori, George Kyei Agyen, Alfred Effah   +6 more
doaj   +2 more sources

Clinical Resistance to Lenacapavir During Treatment of HIV Infection: A Review [PDF]

Viruses
Lenacapavir (LEN) is the first-in-class capsid inhibitor that inhibits HIV capsid function in vitro with picomolar activity. LEN has been approved for the treatment of HIV in combination with other antiretroviral agents (ARVs), as well as for the ...
Nicolas A. Margot, Christian Callebaut
doaj   +2 more sources

Drivers of Vertical HIV Transmission in Sub‐Saharan Africa and the Impact and Cost‐Effectiveness of Targeted and Universal Lenacapavir Pre‐Exposure Prophylaxis [PDF]

Journal of the International AIDS Society
Introduction Eliminating vertical HIV transmission remains a major public health priority, particularly in sub‐Saharan Africa (SSA), which accounted for 83% of global paediatric HIV acquistions in 2024.
Anna Yakusik, Magdalene K. Walters, Deepak Mattur, Savvy Brar, Leigh F. Johnson, Gesine Meyer‐Rath, Lise Jamieson, Angela Mushavi, John Stover, Mary Mahy   +9 more
doaj   +2 more sources